Long‐term safety of vedolizumab for inflammatory bowel disease

BACKGROUND: Vedolizumab, a gut‐selective α(4)β(7) integrin antibody, is approved for moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). AIM: To report the final results from the vedolizumab GEMINI long‐term safety (LTS) study. METHODS: The phase 3, open‐label GEMINI...

Descripción completa

Detalles Bibliográficos
Autores principales: Loftus, Edward V., Feagan, Brian G., Panaccione, Remo, Colombel, Jean‐Frédéric, Sandborn, William J., Sands, Bruce E., Danese, Silvio, D’Haens, Geert, Rubin, David T., Shafran, Ira, Parfionovas, Andrejus, Rogers, Raquel, Lirio, Richard A., Vermeire, Séverine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Efficacy and Safety of Biologics for Crohn's Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540482/
https://www.ncbi.nlm.nih.gov/pubmed/32876349
http://dx.doi.org/10.1111/apt.16060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540482/
https://www.ncbi.nlm.nih.gov/pubmed/32876349
http://dx.doi.org/10.1111/apt.16060

Ejemplares similares